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So we can actually make only a rough estimate of the
costs of the PTCA procedure. From the results of the
•i French registry, one can only estimate, taking into
account the costs of the procedure per se, taking into
" 'account that in some patients the lesions were not
crossed, and these patients were not necessarily
treated by bypass surgery, taking into account the rate
" of emergency, bypass grafting, taking into account the
rate of restenosis of 35%, that, within the last 5 years
'" from 1980 to 1985, PTCA has cost in France approx.
, .FF122 000 000 or approx. $18 300 000. If we apply the
same coefficient of 3 between PTCA and bypass
* surgery, one can estimate that if these patients had
been operated on, the costs would have been
FF 360 000 000 or $55 million. That means that the
. economy achieved was possibly FF 244 millions or $36
millions.
If we compare information from eleven centres
in France on the respective percentage of the
number of PTCA and on the number of bypass
grafts per year, we can observe that in 1980, 92%
of the patients with suitable lesions for myocardial
revascularization have been treated by bypass
graft, but in 1985 only 38% of them are being
treated by an operation and the greatest number
have been treated by PTCA procedure. But if we
look to the absolute number of procedures per
year, we have a simultaneous increase of the
PTCA procedure for the 11 centres and the
number of bypass grafts. And this is why I believe
that in France and probably in many other
countries, it is difficult to convince hospital mana-
gers and the Ministry of Health that PTCA is
cheaper than coronary bypass surgery.
The need for coronary artery surgery: expand or restrict?
a European view
M. E. ROTHUN
University Hospital, Zurich, Switzerland
The aorto-coronary bypass operation, which was
_ introduced during the late nineteen sixties, has
become the most efficient treatment of patients
- with ischaemic heart disease, which causes angina
pectoris, heart failure, myocardial infarction or
'sudden death. During the last 15 years continual
„ improvement of patient selection, surgical tech-
niques, perioperative and postoperative manage-
* ment has resulted in a very low mortality from this
operation (comprising 1-2%) and a very high
success rate.
• Ischaemic heart disease being the most common
disease in Western industrial countries and the cost
"i of aorto-coronary bypass being very high, the
community represented by public health depart-
ments, insurance institutions, politicians, hospital
,- administrators and, last but not least, medical men
shows great interest: how big a slice of the resource
1
 'cake for medical care is taken by aorto-coronary
bypass surgery?
Benefit and indications for aorto-coronary bypass
. surgery
^ In well-controlled studies on the effect of aorto-
coronary bypass operations it has been confirmed
that this procedure is superior to any drug treat-
ment in relieving angina pectoris. Moreover the
objective effort tolerance of patients who have
received the operation is higher than that of
patients on drug treatment alone and the drug
requirement of patients after aorto-coronary by-
pass is considerably lower than for medically
treated subjects'1"31.
On these observations there is general agree-
ment. Controversy starts when this experience is
being used in the decision making on how to treat a
specific patient suffering from effort angina. Many
clinicians support the view that a trial of drug
treatment of several weeks or months should
precede more specific investigation in all patients
presenting with stable angina pectoris. This at-
titude is likely to reduce the number of an-
giographies and operative procedures, but we must
also look at its drawbacks. During the delay a few
patients will experience possibly avoidable coro-
nary events such as myocardial infarction or sud-
den death. Many more will get used to their
chronic condition. Their insecurity and fear of
angina or worse make a change in their life style. If
they become unemployed their daily schedule and
activities will change. However, owing to their
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Figure 1 Effect of aorto-coronary artery bypass surgery on five-year survival
in the prospective randomised ECSSG and CASS trials (m—multiple)
physical inactivity and to their drug regimen angina
appears to improve. This may be satisfactory for
many elderly subjects with a contemplative mode
of life, but for a large number of patients, who
experience angina pectoris in the middle of an
active life, with family obligations, professional
responsibilities or for enthusiastic sportsmen, such
a passive attitude becomes unacceptable as soon as
they learn of an alternative option promising return
of previous physical ability without symptoms and
a reduction of daily medication. For these patients
a 6 to 8 month delay of active measures may
irreversibly affect their psychological and economic
future. There is obviously a wide range of subjec-
tive decisions to be made by the primary physician,
which depends upon his expert assessment of the
symptoms being presented, the general health
status, and the personality of each individual
patient. On the other hand, aorto-coronary bypass
operations may prolong life in certain patients. This
issue is most controversial because it has crucial
consequences on the decision as to whether surgical
treatment is superior to conventional management
or not, The effect of aorto-coronary bypass has
been studied by numerous investigators. In three
large prospective trials selected patients were as-
signed at random to medical or surgical treatment
and were closely followed afterwards|2lO). In one
of these studies carried out in Europe121 it was
found, that the operated patient group had a
significantly better survival than the conventionally
treated group. The more recent CASS study from
the United States'51 showed no significant
difference between surgically and non-surgically
treated patients. However in this study all patients
had an excellent prognosis. From the clinical trials
we may conclude that the effect of aorto-coronary
bypass on mortality depends on patient selection.
It is obvious, that it is most difficult to improve
substantially a mortality rate which is very low.
Julian has pointed out in a recent article on .
randomized trials, that the results of both the
European and the CASS study are compatible*
(Fig. 1), the one showing a significant and the
other an insignificant improvement of mortality.
However the 95% confidence limits of both results ,
show a considerable overlap. Most experts agree
that there exist patients whose prognosis can be "
improved by aorto-coronary bypass. What we have^
to clarify more precisely, are the criteria to define
patients at high risk, which can be improved by
surgery. Thereafter large consecutive patient series
including all aorto-coronary bypass operations per- >
formed at a centre should be analysed looking for ,
the proportion of patients, whose prognosis is
thought to be improved by surgery.
Alternative and complementary measures *
Aorto-coronary bypass certainly is not a panacea ,
against ischaemic heart disease and non-surgical
therapy has not stood still. Changing habits may be '
responsible for the decreasing incidence of is-
chaemic heart disease in the United States. At
least, stop smoking has been convincingly docu-,.
mented to reduce the mortality of patients with
ischaemic heart disease. For other factors such as ''
increased physical activity and change of dietary
habits there is circumstantial evidence of benefit.
However, all these mechanisms take considerable -
time to become manifest and to result in a substan-
tial reduction of the number of patients with"
ischaemic heart disease.
Several drugs, such as beta-receptor-blocking-
agents, aspirin and possibly, calcium-channel in-
hibitors or lipid lowering substances may improve
prognosis in subsets of patients with ischaemic
heart disease. All these measures are not alterna-,
tives but complementary to ACBP surgery.
Coronary artery surgery 53
800
° 600
% 400
200
a B CH CS FRG GDR E F FS H I N NL P S UK USA
» Figure 2 Number of aorto-coronary artery bypass operations performed in
different European countries and in the U.S.A. during the year 1985.
The introduction of balloon dilatation of coro-
nary obstructive lesions by Griintzig, using a cathe-
^ ter system introduced percutaneously into the fem-
oral artery may avoid surgical intervention. This
• procedure has gained wide application; it's perfec-
tion and the additional use of laser techniques may
avoid aorto-coronary bypass in selected patients.
However, it is most likely that this measure will
rather postpone than replace surgery in the majo-
*• rity of the candidates.
"'Cost of aorto-coronary bypass
The cost of aorto-coronary bypass surgery varies
from one institution to another. The cost price of a
bypass operation can only be estimated, because
hospital charges do not necessarely reflect it. In the
public medical system cost price seems to be about
*SFr 20 000, while it is SFr 30 000 for a private
patient. The cost of preoperative diagnostic inves-
tigations is about SFr 3500 and 6000, respectively,
for the public and private medical system. If
postoperatively patients enrol in an institutional
rehabilitation program, another SFr 5000 or 7000
» have to be added resulting in a sum of SFr 28 500
and 43 000, respectively, for the two medical sys-
tems. Lichtlen estimates a similar cost of DM
50 000 per procedure in the F.R.G. while from the
U.S.A. expenses around $20 000 have been re-
ported for the surgical procedure alone.
Last year about 250 operations were performed
per one million population in Switzerland, assum-
ing a price of SFr 40 000, about SFr 65 000 000 have
been spent for aorto-coronary bypass correspond-
ing close to 1% of the total expenses of the Swiss
health insurance institutions and to less than 1/2%
of the total expenses for health care.
Cost-benefit analysis
A cost-benefit analysis in the strict sense of the
term seems to be most difficult for physicians
because we cannot convert health care benefits into
DM, £ or SFr. One way of assessment of cost-
benefit ratio is analysing the return to work after
aorto-coronary bypass. This problem has been
thoroughly discussed during a symposium or-
ganized by the International and German Societies
of Cardiothoracic Surgery two years ago16'. Al-
though many patients are enabled to resume their
previous vocational activity after aorto-coronary
bypass, there is considerable question as to this
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benefit in most statistical studies on that subject. A
major factor for not resuming gainful employment
was found to be the delay in definite diagnosis, in
taking the decision for angdography and surgery as
well as the delay caused by waiting lists for
diagnostic and therapeutic procedures.
Number of aorto-coronary bypass operations in
European countries
During a recent symposium in Salzburg, Unger
collected figures on the number of bypass opera-
tions performed in European countries. It can be
seen in Fig. 2, that these figures vary from 30
operations per year and one million inhabitants up
to 475 in the Netherlands, as compared to 800
interventions per one million in the U.S.A. We
have to keep in mind that the prevalence of
ischaemic heart disease varies from country to
country. Therefore it was proposed by the Dutch
Heart Foundation to compare the number of
operations per year with the corresponding mortality
figures and it was found, that during 1982 in the
United States the number of yearly operations
corresponded to 31% of all subjects succumbing to
ischaemic heart disease, in the Netherlands to
20%, in Switzerland to 12% and in the United
Kingdom to 4% only. Such a difference in manage-
ment is not only seen from one country to the
other but may exist in each individual country as
was observed in an ongoing study by Gutzwyler
carried out on the number of coronary angio-
graphies performed for each 100 000 residents of
the 26 Swiss cantons'8'. In rural areas a much
fewer number of patients undergo this diagnostic
procedure than in urban agglomerations. Moreover
more angiographies were performed in the South-
western French speaking part as compared to the
German speaking areas.
The trend of the numbers of aorto-coronary
bypass at the University Hospital of Zurich shows a
steady increase within the last decade, which is
responsible for the total rise of heart surgery with
extracorporal circulation. Very similar observations
have been made for the Netherlands and for the
Federal Republic of Germany.
Factors influencing patient referal for aorto-
coronary bypass surgery
Before I estimate the number of aorto-coronary
bypass operations for the nineteen nineties, I
briefly review the factors influencing patient referal
in the future. Newly accepted indications for sur-
gery, i.e. prompt operation in patients with sud-
denly aggravating angina pectoris and compatible >
angiographic findings will increase the number of
operations. Improving operative experience results
in a lower mortality and better success rate en-
 T
couraging physicians to refer their patients for
operation. Furthermore I have demonstrated that "•
there are very considerable regional differences in
patient referal and it may be expected, that more
patients will be sent for invasive diagnostic study.,
and surgery from areas, where for the time being
patient management is most conservative. On the '
other hand, the declining incidence of ischaemic ^
heart disease would be a factor reducing patient
referal; however, such a favorable development -
has yet to occur in the European countries. Fur-
thermore it remains to be shown, that newer*
therapeutic options such as balloon dilatation of
coronary stenosis significantly reduce the number
of bypass operations performed. Finally, there are
economic factors influencing coronary artery sur-
gery. Waiting lists for diagnostic investigations and
surgical treatment result in a delay of 4-8 months „
in many heart surgical centres throughout Europe
and discourage physicians from proposing surgical
revascularisation to their patient. However to me-
dical men seeking for the optimal treatment of '
their patients this attitude of deliberate restriction
of treatment facilities is not an acceptable one.
Nevertheless, a declining economical situation is an '
uncertain variable that might limit the feasibility of
costly medical procedures in the future.
Anticipated number of aorto-coronary bypass
operations
For an assessment of the future development of'
aorto-coronary bypass in Switzerland I made arv
inquiry with heart surgeons and cardiologists at the
five Swiss University Hospitals. Close to 250 oper- '
ations per one million were performed in 1985.
Asked for the anticipated number of bypass opera-
tions in the early nineties all heart surgeons and all..
but one cardiologists predict an increase from the
present figures. The lowest estimate for the num-*"
ber of operations in the early nineties was 250 per
one million while the majority of the answers
indicate a lower limit of 350 operations. My
personal prediction would be 350-400 operations
per million and year and this seems to be com-
patible with the estimate of most of my medical,
and surgical colleagues.
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Summary
I have been solicited by the organizers not to
present a final solution to the problem, but to
^comment on controversial issues.
For the indications for aorto-coronary bypass,
"" consensus has been reached by most medical men
^ that angina pectoris and, in selected patients,
prognostic considerations are important. Contro-
- versy starts when we ask how much angina or what
pattern of clinical and angiographic risk factors are
* required for the operative indication.
„ It remains to be seen, whether other forms of
mechanical revascularisation, such as balloon dila-
i
 tation can replace surgery in large numbers of
patients, who are presently treated by aorto-
coronary bypass.
. An effort has been made by physicians to make
greater use of cost-benefit analysis estimates in
- their medical decisions, and to provide policy
makers with this information.
The number of aorto-coronary bypass operations
. in European countries varies considerably. The
trend of these figures, however, is rising through-
o u t Europe and therefore my personal answer to
the crucial question in the title is: expand.
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What will be the requirements for acute interventional procedures
in Europe?
P. W. SERRUYS AND A. DEN BOER
Rotterdam, The Netherlands
The needs and the requirements are changing with
such a pace that it is almost impossible to foresee
-.what is going to happen within 5 years or even
within 2 years. An inventory of interventional
' cardiac catheterization procedures (Table 1) shows
that no. 1 is still percutaneous transluminal coro-
nary angioplasty carried out by means of a balloon,
- a laser or by spark erosion1'-2'. These last two
techniques are really to drill CTaters into athero-
*"sclerotic plaques. We believe that transluminal
( angioscopy will be necessary to keep the side-
effects of these two powerful tools under control'3'.
Transluminal coronary recanalization and an-
gioplasty in acute myocardial infarction, although
extensively applied, is still under clinical
^ investigation1'01. New techniques such as trans-
luminal atherectomy have been recently introduced
and tested in human beings, but only on peripheral
vessels'6'. For more than 10 years investigators
have tried to supply the ischaemic myocardium
with oxygenated blood through the coronary
sinus'7'. Pulsatile retroperfusion of coronary sinus
with oxygenated blood has been attempted in a few
patients with unstable angina or during an-
gioplasty. Intermittent coronary sinus occlusion
seems to be another possible approach. Several
percutaneous left ventricular assist devices are still
under development; the most commonly used is
intra-aortic balloon counterpulsation.
In 1984/1985 in Europe percutaneous balloon
valvuloplasty began to be applied to acquired
valvular disease. Congenital pulmonary stenosis
was already an established indication when French
cardiologists started to dilate calcified aortic valves
